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Purpose: Testosterone is essential for the prostate gland’s normal growth and develop-
ment and is also a possible risk factor for prostate cancer. This study’s aim was to de-
termine the significance of serum testosterone for prostate-specific antigen (PSA) ele-
vation and prostate cancer prediction in high-risk men.
Materials and Methods: The study included 120 patients with PSA ＞10 ng/ml who un-
derwent a transrectal-prostate biopsy. Serum testosterone, prostate volume, and PSA 
density (PSAD) were checked in all patients. Patients were divided into two groups, 
patients with and those without prostate cancer; and testosterone-related factors, pros-
tate volume, PSA, PSAD, age, prostate cancer prediction rate, and cancer aggressive-
ness were evaluated.
Results: Thirty-five patients (30.2%) were confirmed as having prostate cancer. The 
average serum testosterone level in patients without and in those with prostate cancer 
was 452.25±154.62 ng/dl and 458.10±158.84 ng/dl, respectively; average PSA was 
17.58±9.02 ng/ml and 18.62±6.53 ng/ml, respectively; and average age was 69.02±7.52
years and 70.69±7.02 years, respectively (p＞0.05). Hypogonadal and eugonadal pa-
tients showed no significant difference in cancer prevalence (30.3% vs. 32.0%, re-
spectively). The testosterone level did not differ significantly in patients with and those 
without prostate cancer in either hypogonadal or eugonadal men (p＞0.05). Serum tes-
tosterone showed no correlation with PSA, PSAD, or age in either group (p＞0.05) and 
was unrelated to prostate cancer risk or aggressiveness (p＞0.05).
Conclusions: In our study’s results, serum testosterone at the time of diagnosis was 
unrelated to PSA elevation, prostate cancer risk, and aggressiveness.
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INTRODUCTION
Testosterone is essential for the normal growth and devel-
opment of the prostate gland and is also a possible risk fac-
tor for prostate cancer [1,2]. Huggins and Hodges’s seminal 
work in the 1940s first demonstrated the hormone depend-
ence of prostate cancer [3], consequently establishing tes-
tosterone as a key therapeutic target for managing pros-
tate cancer. Androgen deprivation therapy to lower the se-
rum testosterone level remains a standard treatment for 
advanced disease to the present day. Isbarn et al’s recent 
studies, however, show a result opposite that of Huggins 
and Hodges, implying that testosterone neither increases 
the risk of prostate cancer nor causes cancer recurrence in 
men who have been treated successfully for prostate cancer 
[4]. A recent study by Morote et al showed that prostate can-
cer risk and tumor aggressiveness are unrelated to serum 
testosterone [5]. Other recent epidemiologic studies also 
have found no association between testosterone and pros-
tate cancer [6-10].Korean J Urol 2010;51:831-835
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TABLE 1. Clinical and laboratory features in men with and those without prostate cancer
Without prostate cancer
(n=85, Mean±SD)
Prostate cancer
(n=35, Mean±SD)
p-value
Age (yr)
Prostate volume (g)
PSA (ng/ml)
Serum testosterone (ng/dl)
　＜300
　≥300
PSA density
69.02±7.52
41.48±17.10
17.58±9.02
452.25±154.62
251.35±43.61
506.22±126.40
0.26±0.18
70.69±7.02
36.77±16.73
18.62±6.53
458.10±158.84
248.16±50.41
501.52±137.06
0.37±0.26
0.265
0.171
0.105
0.852
0.880
0.871
 0.012
a
PSA: prostate-specific antigen, 
a: statistically significant
TABLE 2. Pearson correlation coefficients (p-value) for possible 
correlation with serum testosterone
Benign biopsy Prostate cancer
Age
Prostate volume
PSA
PSA density
Gleason score
−0.058 (0.597)
−0.039 (0.720)
−0.056 (0.611)
−0.083 (0.451)
-
0.101 (0.565)
−0.211 (0.990)
−0.241 (0.163)
−0.081 (0.6466)
0.239 (0.166)
PSA: prostate-specific antigen
TABLE 3. Binary logistic regression analysis of prostate cancer 
risk predictors
Variable Odds ratio (95% CI) p-value
Age
Prostate volume
Serum testosterone 
PSA
PSA density
1.030 (0.97-1.093)
1.002 (0.957-1.048)
0.999 (0.996-1.003)
0.999 (0.861-1.158)
28.653 (0.99-8,252.572)
0.320
0.937
0.646
0.986
0.246
CI: confidence interval, PSA: prostate-specific antigen
　Our main objective was to analyze the relationship be-
tween serum testosterone, prostate-specific antigen (PSA), 
and prostate cancer risk in high-risk patients.
MATERIALS AND METHODS
The study population consisted of 120 men with a PSA level 
of 10 ng/ml or higher. The data were collected from January 
2008 to January 2010. To determine the relationship be-
tween testosterone, PSA, and prostate cancer risk in a 
high-risk group, we limited our study population to men 
with a PSA level of 10 ng/ml or higher. We excluded from 
this analysis men who were taking medications known to 
lower PSA, such as finasteride or dutasteride. All men were 
assessed by a transrectal ultrasound (TRUS)-guided biop-
sy of the prostate. Twelve cores were obtained and two extra 
biopsies were taken if hypoechoic or otherwise suspicious 
areas were noted on ultrasound. 
　Serum testosterone levels were measured by using a sol-
id-phase competitive chemiluminescent enzyme immuno-
assay with the Advia Centaur
Ⓡ Immunoassay system 
(Bayer Health Care, Chicago, IL, USA). Blood samples 
were taken between 8 am and 10 am and were processed 
immediately.
　We classified the men as hypogonadal if their serum tes-
tosterone level was ＜300 ng/dl, according to the criteria 
used by Rhoden et al [11].
　For possible correlation between serum testosterone, 
PSA, and prostate cancer, we included age, PSA density 
(PSAD), prostate volume, and Gleason score for patients 
with prostate cancer. Statistical analysis was performed by 
using the Student’s t-test, the Pearson correlation test, sim-
ple linear regression, and binary logistic regression. Odds 
ratios with 95% confidence intervals (CIs) for PSA, PSAD, 
serum testosterone, and age were determined to predict 
prostate cancer risk. All data are presented as the Mean±2 
SD to define and characterize quantitative variables and 
as percentages to characterize qualitative variables; we 
considered a p-value＜0.05 to be statistically significant.
RESULTS
Out of 120 patients, the samples of 85 (70.1%) patients were 
diagnosed as benign and those of 35 (29.2%) patients were 
diagnosed as being prostate cancer. There was no sig-
nificant difference in the patient’s average age, PSA, pros-
tate volume, or testosterone between patients without and 
those with prostate cancer. Only PSAD differed signi-
ficantly between the two groups (t-test, p=0.012) (Table 1). 
Hypogonadism was diagnosed in 24 men. Hypogonadal and 
eugonadal men did not differ significantly in cancer de-
tection rate (30.2% vs. 32.0%, respectively). The testoster-
one level did not differ significantly between patients with-
out and those with prostate cancer in either hypogonadal 
(248.16±50.41 ng/dl vs. 251.35±43.61 ng/dl, respectively) 
or eugonadal (501.52±137.06 ng/dl vs. 506.22±126.40 ng/dl, 
respectively) men (t-test, p＞0.05). Testosterone was un-
related to age, PSA, PSAD, or prostate volume in both men 
without and those with prostate cancer, and prostate can-
cer aggressiveness also was unrelated to serum testoster-
one in prostate cancer patients (p＞0.05) (Table 2). The bi-
nary logistic regression also confirmed that none of the vari-
ables used in this study was an independent predictor of 
prostate cancer risk for men with a PSA level ＞10 ng/ml Korean J Urol 2010;51:831-835
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FIG. 1. Scatterplots showing the effect of testosterone on PSA. 
PSA: prostate-specific antigen.
TABLE 4. Prostate cancer prevalence according to testosterone
levels
Testosterone range 
(ng/ml)
n Cancer Percentage
150-199
200-249
250-299
300-349
350-399
400-449
450-499
500-549
550-599
600-649
650 or higher
4
7
13
11
12
10
13
19
10
9
11
1
2
3
3
4
2
3
5
3
4
2
25.0
28.6
23.1
27.3
33.3
20.0
23.1
26.3
30.0
44.4
18.2
(p＞0.05) (Table 3). Further evaluation with simple linear 
regression confirmed that testosterone and PSA did not 
show any correlation (p＞0.05) (Fig. 1). When we divided 
the patients into 11 groups according to their testosterone 
level, within a 150 ng/dl range, prostate cancer prevalence 
did not change as the testosterone level increased (p＞0.05) 
(Table 4).
DISCUSSION
In men, the Leydig cells in the testes produce approxi-
mately 90% of testosterone; the adrenal glands produce the 
rest. Testosterone plays a key role in the development of 
male reproductive tissues such as the testes and prostate 
gland [12]. Under testosterone influence, the prostate 
gland experiences two main growth periods. The first oc-
curs early in puberty, when the prostate doubles in size. At 
around age 25, the gland begins to grow again. When the 
prostate is growing, testosterone is converted into dihy-
drotestosterone (DHT), which is the androgen receptor’s 
major activator [13,14]. After DTH binds to androgen re-
ceptors, it translocates to the nucleus, where it mediates 
the transcriptional activation of target genes [15]. These 
androgen-stimulated changes in gene expression promote 
cellular growth, which often results in benign prostatic hy-
perplasia in elderly men. 
　Long-term cessation of the prostate’s exposure to an-
drogen appears to protect against the development of can-
cer, but no dose-response relationship between testoster-
one level and cancer risk has been established. The pros-
tate cancer risk for men with a testosterone concentration 
in the normal range remains unclear [16]. Recent chemo-
preventive trials with 5-alpha-reductase inhibitors show 
the role of testosterone in prostate cancer development 
[17]. Finasteride reduced the risk of prostate cancer by 
24.8% compared with a placebo in healthy men [18]. 
Recently, the REDUCE study showed that dutasteride also 
reduced the risk of prostate cancer by 23% compared with 
a placebo in healthy men [19].
　Huggins and Hodges first showed the effect of testoster-
one on prostate cancer patients in 1941 [3]. They showed 
the hormonal responsiveness of prostate cancer by report-
ing that markedly reducing the testosterone level by cas-
tration and estrogen treatment caused metastatic prostate 
cancer to regress, and injecting testosterone caused pros-
tate cancer to grow. In 1995 Wu et al found that the dis-
tribution of dihydrotestosterone-to-testosterone ratios pa-
rallels both the incidence of and mortality from prostate 
cancer [20].
　The demonstration that androgen suppression effec-
tively treats advanced prostate cancer, and the fact that 
elevated serum androgen levels might predispose people 
to prostate cancer, have attracted persistent interest. 
However, a recent study refuted any connection between 
elevated testosterone levels and increased prostate cancer 
risk [10,21]. Endogenous Hormones and Prostate Cancer 
Collaborative Group et al meta-analyzed the serum con-
centrations of sex hormones from subjects in 18 prospective 
studies that included 3,886 men with incident prostate 
cancer and 6,438 control subjects [10]. They concluded that 
endogenous hormones, including testosterone, were not 
associated with prostate cancer. 
　Morote et al recently conducted another study of 478 pa-
tients [5], all of whom were assessed by TRUS-guided pros-
tate biopsy because of an abnormal digital rectal examina-
tion, PSA ＞4 ng/ml, or both. They found no difference in 
serum testosterone level between patients with and those 
without prostate cancer and concluded that the serum tes-
tosterone level was not associated with prostate cancer risk 
or aggressiveness.
　An animal study by Morgentaler and Traish showed that 
beyond a certain serum testosterone concentration, an-
drogens have a limited ability to stimulate prostate cancer 
growth [22]. Subsequent increases in serum testosterone 
levels beyond that concentration did not stimulate the 
prostate because the binding capacity of the intra-prostatic 
androgen receptors had been saturated.
　Our results are similar to those of the above studies even 
though we limited our study population to patients with Korean J Urol 2010;51:831-835
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PSA ＞10 ng/ml. We found that the serum testosterone lev-
el at the time of diagnosis was unrelated to PSA and pros-
tate cancer risk and aggressiveness in both hypogonadal 
and eugonadal patients. 
　Ideas about the interaction between testosterone and 
prostate cancer have changed considerably over the past 
decade. Like our study, most recent epidemiologic studies 
have found no association between testosterone and pros-
tate cancer [6-10]. A few studies published during the past 
decade contrast with our results, however, and show that 
low testosterone levels seem to be related to an increased 
risk of prostate cancer and tumor aggressiveness, such as 
a high Gleason score [23-28]. 
　In our study, we compared age, PSA, prostate volume, 
and PSAD with testosterone. Only a known prostate cancer 
predictor, PSAD, showed a significant difference between 
patients with and those without prostate cancer, even in 
high-risk patients with a PSA level of 10 ng/ml or higher. 
Patients without prostate cancer had relatively lower PSA 
and larger prostates than did patients with prostate 
cancer. However, our binary logistic regression showed 
that PSAD was unsuitable as an independent predictor of 
prostate cancer risk in men with a PSA level of 10 ng/ml 
or higher. Furthermore, prostate cancer prevalence did not 
increase as testosterone levels increased.
　Our study had several limitations. We measured the se-
rum testosterone level in the patients only once, before 
their biopsy was done. Second, we checked only their total 
testosterone level and were unable to check their free tes-
tosterone level. Finally, our study population was smaller 
than those of other studies.
　In summary, the present study found that the serum tes-
tosterone level at the time of diagnosis was unrelated to 
PSA and prostate cancer risk and aggressiveness. Because 
testosterone levels change with age and time, a prospective 
study with long-term testosterone monitoring is required 
to find a relationship between testosterone and prostate 
cancer.
CONCLUSIONS
Our results show that the serum testosterone level at the 
time of diagnosis was unrelated to PSA and prostate cancer 
risk and aggressiveness. Additional studies with long- 
term follow-up are needed to explain the possible mecha-
nism and relationship between testosterone, prostate can-
cer, and PSA.
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